Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
(A joint stock company established in the People's Republic of China with limited liability)
(Stock Code: 9887)

VOLUNTARY ANNOUNCEMENT
OBLENIO EXERCISED OPTION TO RETAIN ITS LICENSE FOR LBL-051

This announcement is made by Nanjing Leads Biolabs Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**" or "**we**") on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Company.

Reference is made to the announcements (the "**Announcements**") of the Company published on June 25, 2026 and August 4, 2026 in relation to, among other matters, (i) the closing of the Series B financing round for Oblenio Bio, Inc. ("**NewCo**"); and (ii) the dosage of first patients in the Phase Ia first in human clinical trial of LBL-051 in Europe. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

On November 5, 2024, we entered into a collaboration, exclusive option and license agreement (the "**Oblenio Agreement**") with NewCo, a U.S. company formed by Aditum Bio. Under the Oblenio Agreement, we grant NewCo an exclusive, worldwide license to develop, manufacture and commercialize LBL-051, subject to NewCo's election to exercise its option (the "**Option**") to retain such license following the applicable option period.

On August 19, 2026, Leads Biolabs Inc. ("**Leads US**"), the Company's subsidiary, received a written option-exercise notice from NewCo. Pursuant to the Oblenio Agreement, upon exercise of the Option, NewCo shall pay Leads US a one-time, non-refundable, and non-creditable fee of US$10,000,000. The exercise of the Option marks an important milestone in the collaboration and sets the stage for the further progress of LBL-051 in global clinical development and commercialization. More importantly, it represents a vote of confidence in the ongoing clinical progress of our TCE platform in autoimmune diseases, a key therapeutic area.

About LBL-051

LBL-051 was discovered and engineered using the Company's proprietary LeadsBody™ platform. By simultaneously targeting BCMA, CD19 and CD3, LBL-051 is uniquely designed to deplete a broader spectrum of pathogenic B-cell and plasma cell populations, offering the potential for deeper and more durable responses compared to single-target or bispecific approaches. This immune reset strategy aims to achieve long-term drug-free remission for patients suffering from a range of refractory autoimmune diseases.

Preclinical data presented by NewCo at the 2026 European Congress of Rheumatology (EULAR 2026) demonstrated that step-up dosing of LBL-051 resulted in complete depletion of peripheral and tissue B-cells and plasma cells in non-human primates, with consequent emergence of immature, non-memory B-cells in the blood upon recovery – findings consistent with changes described in autoimmune patients achieving long-lasting drug-free remissions in the clinic. Importantly, the study showed that the treatment did not cause cytokine release syndrome (CRS), including at high exposure levels, and demonstrated dose-dependent decreases in peripheral blood immunoglobulins, consistent with plasma cell depletion.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market, LBL-051, successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
Dr. KANG XIAOQIANG
Chairman, Executive Director and Chief Executive Officer

Nanjing, PRC, August 19, 2026

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Wu Fenglan as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive Directors.